For the last nine months, I have been covering small biotechs ranging from those working on COVID-19 diagnostics and vaccine development to larger bio-pharmas with manufacturing capability.
My experience tells me that we are now at a critical juncture in the value chain from development in the lab to availability on the field.
Some news about governments in the US, Europe, and Australia reaching agreements with pharmaceuticals companies for availability of vaccines also point to a shift of attention towards manufacturers.
In this respect, one of the companies which is capable of doing both development